<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00947193</url>
  </required_header>
  <id_info>
    <org_study_id>PTC124-GD-011-HEM</org_study_id>
    <nct_id>NCT00947193</nct_id>
  </id_info>
  <brief_title>Study of Ataluren (PTC124®) in Hemophilia A and B</brief_title>
  <official_title>A Phase 2a Study of Ataluren (PTC124) as an Oral Treatment for Nonsense-Mutation-Mediated Hemophilia A and B</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PTC Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genzyme, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>PTC Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hemophilia A (HA) and hemophilia B (HB) are inherited bleeding disorders caused by mutations
      in the gene for factor VIII (FVIII) and factor IX (FIX), respectively. These proteins are
      essential for blood clotting. The lack of FVIII/FIX can produce bleeding episodes that cause
      damage of the bone, muscles, joints, and tissues. A specific type of mutation, called a
      nonsense (premature stop codon) mutation, is the cause of the disease in approximately 10-30%
      of patients with hemophilia and results in severe manifestations. Ataluren (PTC124) is an
      orally delivered, investigational drug that acts to overcome the effects of the premature
      stop codon, potentially enabling the production of functional FVIII/FIX. This study is a
      Phase 2a trial evaluating the safety and efficacy of ataluren in patients with HA or HB due
      to a nonsense mutation. The main purpose of this study is to understand whether ataluren can
      safely increase FVIII/FIX activity levels.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, patients with hemophilia A or hemophilia B due to a nonsense mutation will be
      treated with an investigational drug called ataluren (PTC124). Evaluation procedures to
      determine if a patient qualifies for the study will be performed within 14 days prior to the
      start of treatment. Eligible patients who elect to enroll in the study will then participate
      in a 28-day treatment period. Within the 28-day period, ataluren (PTC124) treatment will be
      taken 3 times per day with meals for 14 days at a dose of 10 mg/kg (morning), 10 mg/kg
      (midday) and 20 mg/kg (evening); there will then be an interval of approximately 14 days
      without treatment. During the study, ataluren (PTC124) efficacy, safety, and pharmacokinetics
      will be evaluated periodically with measurement of FVIII/FIX activity and inhibitor levels,
      other blood tests, and urinalysis.
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <start_date>August 2009</start_date>
  <completion_date type="Anticipated">May 2012</completion_date>
  <primary_completion_date type="Anticipated">May 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacological effect as measured by plasma FVIII/FIX activity</measure>
    <time_frame>1.5 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of ataluren (PTC124) on additional markers of disease activity</measure>
    <time_frame>1.5 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety profile of ataluren (PTC124)</measure>
    <time_frame>1.5 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compliance with ataluren (PTC124) administration</measure>
    <time_frame>1.5 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ataluren (PTC124) plasma exposure</measure>
    <time_frame>1.5 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of bleeding episodes</measure>
    <time_frame>1.5 months</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Hemophilia A</condition>
  <condition>Hemophilia B</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ataluren (PTC124)</intervention_name>
    <description>Ataluren (PTC124) will be provided as a vanilla-flavored powder to be mixed with water or milk. Ataluren (PTC124) will be taken 3 times per day, with dosing based on the patient's body weight. The dose level for ataluren (PTC124) will be 10 mg/kg in the morning, 10 mg/kg at midday, and 20 mg/kg in the evening for 14 days.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ability to provide written informed consent

          -  Age ≥18 years

          -  Presence of a nonsense mutation as the sole disease-causing mutation in the FVIII or
             FIX gene

          -  At least 20 prior treatments with FVIII or FIX concentrates

          -  Willingness and ability to comply with scheduled visits, drug administration plan,
             study restrictions, and study procedures

        Exclusion Criteria:

          -  Known hypersensitivity to any of the ingredients or excipients of the study drug

          -  Any history of prior anti-FVIII/FIX inhibitors

          -  Unable or unwilling to forego prophylactic FVIII/FIX concentrate use during the
             screening and on-study periods (Note: Patients are allowed use of FVIII/FIX
             concentrates for treatment of bleeding episodes while on study)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jay Barth, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>PTC Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Bleeding and Clotting Disorders Institute</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincent Indianapolis Hospital</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New England Hemophilia Center</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt Hemostatis and Thrombosis Clinic</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Puget Sound Blood Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Paul's Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z 1Y6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Cardiologique</name>
      <address>
        <city>Lille Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Edouard Herriot</name>
      <address>
        <city>Lyon Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Necker Enfants Malades</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria Careggi Viale G.B. Morgagni</name>
      <address>
        <city>Firenze</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.Bianchi Bonomi Hemophilia and Thrombosis Center</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>France</country>
    <country>Italy</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.ptcbio.com</url>
    <description>PTC Therapeutic's website</description>
  </link>
  <reference>
    <citation>Hirawat S, Welch EM, Elfring GL, Northcutt VJ, Paushkin S, Hwang S, Leonard EM, Almstead NG, Ju W, Peltz SW, Miller LL. Safety, tolerability, and pharmacokinetics of PTC124, a nonaminoglycoside nonsense mutation suppressor, following single- and multiple-dose administration to healthy male and female adult volunteers. J Clin Pharmacol. 2007 Apr;47(4):430-44.</citation>
    <PMID>17389552</PMID>
  </reference>
  <reference>
    <citation>Welch EM, Barton ER, Zhuo J, Tomizawa Y, Friesen WJ, Trifillis P, Paushkin S, Patel M, Trotta CR, Hwang S, Wilde RG, Karp G, Takasugi J, Chen G, Jones S, Ren H, Moon YC, Corson D, Turpoff AA, Campbell JA, Conn MM, Khan A, Almstead NG, Hedrick J, Mollin A, Risher N, Weetall M, Yeh S, Branstrom AA, Colacino JM, Babiak J, Ju WD, Hirawat S, Northcutt VJ, Miller LL, Spatrick P, He F, Kawana M, Feng H, Jacobson A, Peltz SW, Sweeney HL. PTC124 targets genetic disorders caused by nonsense mutations. Nature. 2007 May 3;447(7140):87-91. Epub 2007 Apr 22.</citation>
    <PMID>17450125</PMID>
  </reference>
  <verification_date>October 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 23, 2009</study_first_submitted>
  <study_first_submitted_qc>July 24, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 27, 2009</study_first_posted>
  <last_update_submitted>October 31, 2011</last_update_submitted>
  <last_update_submitted_qc>October 31, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 1, 2011</last_update_posted>
  <responsible_party>
    <name_title>Peter Riebling</name_title>
    <organization>PTC Therapeutics</organization>
  </responsible_party>
  <keyword>Hemophilia A</keyword>
  <keyword>Hemophilia B</keyword>
  <keyword>Factor VIII</keyword>
  <keyword>Factor IX</keyword>
  <keyword>FVIII</keyword>
  <keyword>FIX</keyword>
  <keyword>Nonsense mutation</keyword>
  <keyword>Premature stop codon</keyword>
  <keyword>HA</keyword>
  <keyword>HB</keyword>
  <keyword>PTC124</keyword>
  <keyword>Ataluren</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
    <mesh_term>Hemophilia B</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Factor VIII</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

